Trends of eye lid carcinoma in Chhattisgarh state of India and their outcome with high dose interstitial brachytherapy
Abstract
Introduction: Sight is the most precious of all senses. Tumors of the eye and orbit can be life threatening and causes blindness and disfiguring. In planning management the threat to life with disfigurement is the primary issue to be faced with, the best treatment aimed is to cure and long term control having priority. With this aim our study is to report the trend of eyelid cancer in Chhattisgarh state of India and their outcome with High Dose Rate Interstitial Brachytherapy.
Material and Methods: Thirty Six Patients with histo-pathologically confirmed malignant eyelid tumours previously untreated and registered at the Department of Radiotherapy, Pt. J.N.M. Medical College and Regional Cancer Centre, Raipur, were considered in the present study. Registered patients were classified to find out general trend of occurrence in Chhattisgarh, India. Post- treatment patients were reviewed for five years to study the outcome of high dose rate interstitial brachytherapy (HDRIBRT) of eyelid cancer.
Results and Discussion: Male predominance was seen in the patients of eyelid tumors. The occurrence of eyelid tumour was found higher (72.2%) in the patients with age above 60 years and 27.8% were less than 60 years old. Anatomically majority of malignancies found in upper eyelid than lower eyelid. Post Treatment follow up ranged from 10 months to 5 years in which all the patients remained locally controlled.
Conclusions: Histo-pathologically SCC predominantly found in males than female. The excellent results of interstitial brachytherapy prove that it may be one of the efficient modality for the treatment of carcinoma eyelid.
Downloads
References
2. Dailey Jr, Kennedy RH, Flaharty PM et al. Squamaous cell carcinoma of eye lid. Ophthal Plast Reconstr, Surg. 1994 Sep; 10(3):153-9. [PubMed]
3. Azad SK, Choudhary V. Treatment results of high dose rate interstitial Brachytherapy in carcinoma of eyelid. J Cancer Res Ther. 2011 July; 7(6):157-61. [PubMed]
4. Murchison AP, Wallrath JD, Washington CV. Non surgical treatment of primary non-melanoma eyelid malignancies: A review. Clin Experiment Ophthalmol.2011 Jan; 39(1): 65-83, quiz 92-3. [PubMed]
5. Conill C, Sanchez-Reyes A, Molla M, Vitalta A. Brachytherapy with Ir-192 as treatment of carcinoma of the tarsal structure of the eyelid. Int. J Radiat Oncology Bio. Phys. 2004 Aug; 1;59 (5):1326-9. [PubMed]
6. Avril MF, Auperin A, Margulis A, et al. Basal cell carcinoma of the face: Surgery or Radiotherapy? Results of a randomized study. Br J Cancer. 1997; 76(1):100-6. [PubMed]
7. Daly NJ, De Lafontan B, Combes PF. Results of the treatment of 165 lid carcinomas by iridium wire implant. Int J Radiat Oncol Biol Phys. 1984 Apr; 10(4):455-9. [PubMed]
8. Rio E, Bardet E, Ferron C et al. Interstitial Brachytherapy of periorificial skin carcinomas of the face: A retrospective study of 97 cases. Int J Radiat Oncol Biol Phys. 2005 Nov 1; 63(3):753-7. Epub 2005 May 31. [PubMed]
9. Stannard C, Maree G, Munro R et al. Iodine-125 orbital Brachytherapy with a prosthetic implant in situ. Strahlenther Onkol 2011 May;187 (5):322-7. doi 10. 1007/s 000-011-2177-y. Epub 2011 April26. [PubMed]
10. Willich N. Technical and methodical developments of radiation oncology from a physician’s point of view. Strahlenther Onkol. 2012;188(3):253-2. doi 10. 1007/s 00066-012-0190-4. [PubMed]
11. Petsuksiri J, Frank SJ, Garden AS et al, Out comes after radiotherapy for squamos cell carcinoma of the eyelid. Cancer 2008 Jan;112(1):111-8. doi: 10.1002/cncr.23143. [PubMed]
12. Reifler DM, Hornblass A. Squamos cell carcinoma of the eye lid. Surv. Opthalmol. 1986 May-Jun;30 (6) :349-5. [PubMed]
13. Murchison AP, Walrath JD, Washington CV. Non-surgical treatments of primary, non-melanoma eye lid malignancies: A review. Clinical Experiment Ophthalmol. 2011 Jun; 39(1) : 65-3. quiz 92-3.doi 10.1111/j 1442-9071.2010.02422.x. epub 2011Jan 31.
14. Donaldson MJ, Sullivan TJ, Whitehead KJ and Williamson. Squamos cell Carcinoma of the eyelids. Br. J. Ophthalmol. 2002 Oct; 86 (10):1161-5. [PubMed]
15. Wong VA,Marshall JA, Whitehead KJ et al. Management of periocular basal cell carcinoma with frozen section controlled excision. Opthal Plast Reconst Surg 2002 Nov; 18 (6): 430-5. [PubMed]
16. Daly NJ, De Lafotan B, Combes PF. Results of the treatment of 165 lid carcinomas by Iridium wire implant. Int J Radiat Oncol Biol Phys 1984 April;10 (4):455-9. [PubMed]
17. Conill C, Molla M, Vilalta A Brachytherapy with 192Ir as treatment of carcinoma of the tarsal structure of eyelid. Int J Radiat Oncol boil Phys 2004 Aug; 59 (5):1326-9. [PubMed]
18. Gambaro G, Negri E, Prino et al. Interstitial Brachytherapy with Iridium-192 for carcinomas of the eyelid and inner canthus. Radiother Oncol. 2001; 60(1) (Suppl.1):15- 6. doi 10.1016/s 0167-8140 (01) 80054-2. [PubMed]
19. Green A. Changing patterns in incidence of non-melanoma skin cancer. Epith Cell Biol. 1992 Jan;1 (1):47-1. [PubMed]
20. Doxanas MT, Jackson-Iliff W, Iliff NT, et al. squamous cell carcinoma of the eyelids. Opthalmology. 1987May; 94 (5):539-1. [PubMed]
21. Francis IC, Benecke PS, Kappagoda MB. A ten year hospital survey of eyelid cancer. Aust J Opthalmol. 1984 May; 12 (2):121-7.
OAI - Open Archives Initiative
